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Abstract Chronic obstructive pulmonary disease (COPD)
and asthma are both associated with airflow restriction and
progressive remodeling, which affect the respiratory tract.
Among various biological factors involved in the path-
omechanisms of both diseases, proteolytic enzymes—
matrix metalloproteinases (MMPs)—play an important
role, especially MMP-9. In this review, the authors discuss
the current topics of research concerning the possible role of
MMP-9 in both mentioned diseases. They include the
analysis of protein levels, nucleotide polymorphisms of
MMP-9 gene and their possible correlation with asthma and
COPD. Finally, the authors refer to the studies on MMP-9
inhibition as a new perspective for increasing the effec-
tiveness of treatment in asthma and COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) and
asthma are two main diseases associated with airflow
restriction, which affect the respiratory tract. Due to their
high prevalence, they constitute a serious clinical and
social problem. COPD is currently considered by the
World Health Organization experts to be the fourth cause
of death in the world and its frequency, especially its mild
form, is assessed to be up to 25 % in adults above 40 years
of age (Buist et al. 2007). According to epidemiological
studies, the number of individuals affected by asthma is
estimated at approximately 300 millions (Masoli et al.
2004; Sears 2014).
COPD is characterized by progressive, partially rever-
sible, or irreversible, airway constriction. It is associated
with chronic bronchitis, emphysema and pulmonary
hypertension. The main etiopathogenic factor in COPD is
chronic exposure to tobacco smoke; however, further
deterioration may be associated with upregulation of
chronic inflammatory response to various harmful con-
stituents of air pollution (Global Initiative for Chronic
Obstructive Lung Disease 2010).
Asthma is associated with bronchial constriction in
response to intrinsic or environmental stimuli (Pascual and
Peters 2005). Usually, the intensity and occurrence of
clinical symptoms vary between individuals. The symp-
toms may regress during the course of treatment or
spontaneously. Moreover, between episodes of aggravation
and in remission, patients may not reveal any clinical signs
of disease (Holgate 2007).
Chronic Inflammation
There is no doubt that COPD and asthma are two distinct
diseases with significantly different mechanisms of chronic
inflammatory reaction. In COPD, the inflammation-asso-
ciated changes are demonstrated predominantly in small
airways and lung parenchyma, and result in tissue
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destruction with progressive, irreversible airflow restric-
tion. The main changes in asthma are found in larger
airways and may cause their intermittent and usually
reversible obstruction (Broide 2008; Sethi et al. 2012).
However, also in asthma, the airflow disturbances may be
fixed, especially when involving the distal segments of the
respiratory tract, in small airways, and when associated
with significant thickening of the reticular basement
membrane (RBM) and deposition of the extracellular
matrix components (Broide 2008; Ward et al. 2002). It is
noteworthy that the mentioned changes in RBM are con-
sidered as early features of airway pathology, which may
be parallel or even primary to chronic inflammation (Ward
and Walters 2005).
The main cellular components of both COPD- and
asthma-associated inflammatory reactions are also diverse.
In COPD, in addition to epithelial cells, the main players
are neutrophils and macrophages, whereas in asthma-as-
sociated inflammation eosinophils and mast cells
predominate, with an increasing role of neutrophils during
exacerbations (Fig. 1). On the other hand, some non-asth-
matic patients may display eosinophilic bronchitis,
resulting in fixed airflow obstruction, which is character-
istic for COPD. Moreover, in some exacerbations,
especially those associated with viral infections, increased
neutrophils and eosinophils may be found in both COPD
and asthma (Sethi et al. 2012).
It is an established dogma that each of the mentioned
diseases is controlled by different immunoregulatory/im-
munocompetent cells. In COPD, mainly Th1 and CD8?
lymphocytes are engaged, whereas in asthma the key
players are Th2- and IgE-producing B cells (Fig. 1)
(Broide 2008; Sethi et al. 2012).
According to the diversity mentioned above, the main
cytokines/chemokines also differ in both diseases. In
COPD, the levels of ‘‘regular’’ pro-inflammatory mark-
ers—IL-8, tumor necrosis factor (TNF) and C-reactive
protein—have been found to correlate with disease sever-
ity. At least in some cases, they may result from other co-
morbidities, which are frequently seen in patients with
COPD and are associated with systemic inflammation (e.g.,
diabetes, atherosclerosis, etc.) (Sethi et al. 2012). In con-
trast to COPD, in asthma, markers of ‘‘allergic’’
inflammation—interleukin (IL)-4 and IL-13—predomi-
nate; however, the role of IL-8 and TNF in the
exacerbations has also been postulated (Broide 2008).
Airway Remodeling
In addition to the above discussed inflammatory reactions,
COPD and asthma are both characterized by progressive
changes in respiratory tract, known as remodeling. In
physiological conditions, this term concerns gradual
structural changes of various tissues, which are necessary
for proper formation and development during embryo- and
organogenesis (Jeffery 2001b). However, in the patho-
physiology of the respiratory tract, the remodeling
concerns highly composed structural transformation, which
affects the airways and leads to their significant functional
impairment (James 2005).
There is no agreement on whether the airway remodel-
ing is a consequence of the inflammation, or rather exists as
a distinct phenomenon. As mentioned previously, the main
trigger of inflammatory response in COPD is usually
tobacco smoke or other inhaled constituents of air pollution
(Jeffery 2001a). The prolonged or frequent exposure to
pro-inflammatory agents may promote the development of
chronic form of inflammation with damage and metaplasia
of the respiratory epithelium (Grzela et al. 2013; Haswell
et al. 2010; Lapperre et al. 2007).
It has been suggested that activated epithelial cells may
change their phenotype to mesenchymal ones and this
process is described as epithelial–mesenchymal transition
(Kalluri and Neilson 2003). This observation is consistent
with the concept of aberrant activity of ‘‘epithelial–mes-
enchymal trophic unit’’ (EMTU)—a structural and
functional element in lung organogenesis (Holgate 2010;
Ward and Walters 2005). Stimulated epithelial cells
express large quantities of cytokines/chemokines and
metalloproteinases. Thus, they possibly directly participate
in thickening and also in fragmentation of RBM, charac-
terized by formation of ‘‘clefts’’ (Sohal et al. 2014). The
infiltration of small airways by neutrophils, macrophages
and T lymphocytes is associated with further release of
cytokines and proteolytic enzymes, resulting in the
destruction of alveolar structure and increased mucus
secretion (Sethi et al. 2012). The injured tissues tend to
repair by a process similar to that of scar formation
(Beckett and Howarth 2003; Pascual and Peters 2005;
Ward et al. 2002). However, while exposure to noxious
agents persists, actually this ‘‘repair’’ represents the out-
come of two opposite processes, the enhanced proteolysis
in stroma of pulmonary tissue and extensive fibrosis of the
bronchial tree (Churg et al. 2009; Kranenburg et al. 2006;
Salazar and Herrera 2011).
The airway remodeling occurs also in asthma, although
localization and character of structural changes throughout
the respiratory tract wall are different from those in COPD.
The asthma-associated remodeling consists of RBM
thickening, activation and proliferation of myofibroblasts
and airway smooth muscle cells, and diffuse depositions of
extracellular matrix components—collagen, fibronectin
and proteoglycans (Mauad et al. 2007; Westergren-Thors-
son et al. 2010). Moreover, important constituents of this
remodeling include increased vasculature with angiogenic
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sprouting as well as the number and activity of epithelial
goblet cells and mucous glands (Ward and Walters 2005).
On the other hand, similarly to COPD, epithelial cells in
asthmatics display increased expression of epidermal
growth factor receptors, which may affect the proper
control of epithelial cell cycles and their further behavior
(Broide 2008; Hamilton et al. 2005). Interestingly, it has
been reported that in some patients, RBM changes can
occur even prior to clinical symptoms of asthma (Barbato
et al. 2003). Therefore, the concept of epithelial–mes-
enchymal transition is exploited also in asthma (Holgate
2010).
As mentioned previously, the role of inflammation as a
causative factor in asthma-associated remodeling is
controversial. These controversies may be supported by
observation that in some cases, chronic anti-inflammatory
treatment with inhaled steroids does not completely pre-
vent airway remodeling and has limited influence on the
natural course of asthma in children (Bisgaard et al. 2006).
Interestingly, it has been demonstrated that methacholine-
induced bronchoconstriction may be sufficient to induce
inflammation-independent airways remodeling in patients
with asthma (Grainge et al. 2011). Although the detailed
mechanism responsible for this phenomenon remains
unclear, it may further support the role of EMTU-based
concept in asthma.
COPD and asthma, although significantly different in
their initial or stable stages, display more immunologic and
Fig. 1 The schematic representation of airway mucosa: in a healthy individual (a), structural changes in COPD- (b), and asthma-associated
remodeling (c). The detailed description is given in the text
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molecular similarities in their severe forms and exacerba-
tions. High local concentrations of pro-inflammatory
cytokines/chemokines and fibrosis-promoting factors
maintain the already initiated process (Decramer et al.
2012; Grzela et al. 2013; Rahman and Adcock 2006). A
long list of key players involved in the process includes IL-
8, TNF, fibroblast growth factor, insulin-like growth factor
and, especially, transforming growth factor (TGF)-b (Hol-
gate et al. 1999). TGF-b was found to stimulate collagen
and fibronectin production by fibroblasts and, therefore,
seems to play a crucial role in the induction of peribronchial
fibrosis. Also, it seems to be involved in smooth muscle
cells hyperplasia and mucus hypersecretion (McMillan
et al. 2005; Panettieri et al. 2008; Xie et al. 2007). Simul-
taneously, it was demonstrated that TGF-b may inhibit the
degradation of extracellular matrix components by the
suppressive effect on collagenase expression and, on the
other hand, the upregulation of natural tissue inhibitors of
matrix metalloproteinases (TIMPs) (Wynn 2007). Interest-
ingly, it has also been proven that TGF-b may reveal dual
effect on MMP/TIMP balance, since in in vitro cultured
human lung fibroblasts it stimulated the expression of both
MMP-9 and TIMP-1 (Todorova et al. 2009). Therefore, it is
plausible that airway remodeling followed by peribronchial
fibrosis may result from a TGF-b-mediated mechanism
similar to excessive repair.
Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) constitute a large
family of Zn2?-dependent endoproteinases. So far, at least
25 distinct MMP family members have been identified and,
based on their molecular structure, substrate specificity and
mechanism of activation, classified into four groups—
archetypal MMPs, matrilysins, gelatinases, and furin-acti-
vated MMPs (Fanjul-Ferna´ndez et al. 2010; Grzela et al.
2011; Hadler-Olsen et al. 2011).
MMPs are involved in extracellular matrix turnover and
tissue repair (Crosby and Waters 2010). On the other hand,
however, when out of control they may contribute to tissue
destruction, as found in cancer metastasis, aortic aneurysm,
delayed wound healing, etc. (Birkedal-Hansen et al. 1993;
Klein and Bischoff 2011). Recently, it has been postulated
that some MMPs, especially MMP-9, may also be involved
in respiratory tract remodeling (Salib and Howarth 2003;
Sampsonas et al. 2007).
MMP-9, or gelatinase B, is produced mainly by mac-
rophages and neutrophils, but also by epithelial cells, mast
cells, fibroblasts, and smooth myocytes (Abel and Vlia-
goftis 2008; Kimata et al. 2006; Liang et al. 2007). The
overall scheme of the MMP-9 structure resembles those of
other MMPs. It is composed of a propeptide sequence, the
catalytic domain, fibronectin-like domain and hemopexin-
like domain (Grzela et al. 2011). MMP-9 displays gelati-
nolytic, elastolytic and collagenolytic activity, thus playing
a key role in extracellular matrix turnover. Due to its broad
substrate specificity, in addition to cleavage of extracellular
matrix components, MMP-9 may also modulate the activity
of various biological factors, including other proteinases
(e.g., MMP-13), their inhibitors (e.g., a1-antitrypsin) or
cytokines (e.g., IL-1, VEGF) (Atkinson and Senior 2003;
Engsig et al. 2000; Liu et al. 2000; Patterson and Sang
1997).
MMP-9 in COPD and Asthma
Despite numerous studies conducted so far, current
knowledge regarding the role of MMP-9 in COPD and
asthma is still incomplete. It may, at least partially be due
to methodological difficulties. To get the complete data, the
measurement of the amount of protein, which can be easily
done using simple ELISA, should be supplemented with
some functional assay, reflecting biological activity of
tested factor (Lowrey et al. 2008). In case of MMP-9, the
method routinely used for its functional assessment is the
standard zymography. This semiquantitative method is
based on electrophoresis of tested samples in gelatin-en-
riched SDS/polyacrylamide gel, followed by gel incubation
and visualization. Regrettably, the procedure does not
allow the precise determination of active versus inactive
MMP-9, since it is associated with uncontrolled activation
of pro-MMP during electrophoresis (Grzela et al. 2011).
Moreover, this SDS-mediated activation is difficult to
predict and, therefore, may significantly impair the accu-
racy of assessment in general. Therefore, studies based on
results from the standard zymography alone do not provide
data sufficient for appropriate conclusions and should be
accompanied by alternative in vitro assays, which allow the
assessment of both, activity and amount of MMP-9 (Grzela
et al. 2011). The principle of these assays is to detect the
native enzyme in solution or after its immobilization by the
specific antibody, followed by incubation with labeled
substrate. Depending on the method used for substrate
labeling, the detection system involves standard ELISA
plate reader or more sophisticated equipment, e.g., real-
time thermal cycler device (Grzela et al. 2014).
It is noteworthy that the sensitivity of these assays,
which is similar to ultrasensitive ELISA, is even 20-fold
higher, as compared to standard zymography. Therefore,
they may be the best choice, especially in studies using
material with the expected minute concentrations of MMP-
9, e.g., in exhaled breath condensates (Grzela et al. 2015).
While reviewing studies conducted so far, elevated
MMP-9 was found in blood, sputum and bronchoalveolar
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lavage from patients with asthma exacerbation (Cataldo
et al. 2002; Gagliardo et al. 2009; Lee et al. 2001; Lem-
jabbar et al. 1999). In contrast, no such MMP-9 increase
was found in patients with allergy, but without asthma
(Belleguic et al. 2002). Another observation concerned the
shifted ratio of MMP-9 to its natural inhibitor—TIMP-1—
in bronchoalveolar lavage (BAL) fluid, which was higher
in children with symptomatic asthma, as compared to that
of healthy controls (Erlewyn-Lajeunesse et al. 2008).
Murine models of asthma in MMP-9-deficient animals
have confirmed the involvement of MMP-9 in peri-
bronchial fibrosis. However, MMP-9-deficient animals still
developed smooth muscle thickness, mucus hypersecretion
and bronchial hyperresponsiveness (Lim et al. 2006).
Similarly to asthma-suffering individuals, also COPD
patients displayed increased MMP-9 serum levels, which
moreover correlated negatively with the Tiffeneau–Pinelli
index (FEV1/FVC ratio) (Brajer et al. 2008; Erlewyn-La-
jeunesse et al. 2008). The levels and activity of MMP-9 in
sputum samples from COPD patients were found to be up
to 12-fold higher, as compared to the control group. Both
parameters correlated positively with neutrophil count and
negatively with FEV1 % (of predicted value) (Culpitt et al.
2005). Surprisingly, some other group has shown that
although sputum and BAL samples from COPD patients
contained increased levels of MMP-9, nevertheless, their
activity did not differ between groups (Lowrey et al. 2008).
Furthermore, in the mentioned report, the authors have
observed unexpected positive correlation between MMP-9
activity and FEV1/FVC ratio.
It is noteworthy that MMP-9 is thought to be one of the
key executors in inflammatory reaction. In fact, increased
levels of this protease were also found in acute respiratory
tract diseases, including pneumonia of both bacterial and
viral etiology (Kong et al. 2009; Brand et al. 2012).
Therefore, MMP-9 level cannot be considered as a specific
marker of COPD or asthma. However, the above studies
provide some data, which may suggest its usefulness in
monitoring airway remodeling in both diseases (Cataldo
et al. 2002; Erlewyn-Lajeunesse et al. 2008; Gagliardo
et al. 2009). Therefore, the diagnostic significance of this
factor is still under clinical evaluation.
MMP-9 Polymorphisms
An additional obstacle in MMP research may be the subtle
variability in the molecular structure of the enzyme, which
influences its specific activity. Such alteration may be
determined by natural variation in the DNA sequence
of the MMP gene. These changes, when occurring
with frequency at higher than 1 % of the entire population,
are identified as polymorphisms. Most commonly, the
variability concerns single nucleotide in the gene sequence;
therefore, such polymorphisms are known as single
nucleotide polymorphisms (SNPs). The potential effect of
individual SNP on protein structure and function depends
on its character and position in the target gene structure.
The majority of SNPs are functionally neutral; however,
some of them may result in amino acid substitution, thus
influencing the final protein structure, its biochemical
properties, and, subsequently, physiological function.
Therefore, numerous studies have been conducted so far to
analyze the correlation between various pathologies and
particular SNPs, including those in MMP-9 gene (Grzela
and Bialoszewska 2010; Grzela et al. 2011; Ye 2000, 2006;
Zhang et al. 1999). In fact, several SNPs identified in the
MMP-9 gene were recognized as being associated with
various diseases. Besides the reported correlation between
some MMP-9 SNPs and cancer metastasis, aneurysm for-
mation and atherosclerosis in coronary arteries and also
their possible involvement in COPD and asthma have been
postulated (Ganter et al. 2005; Holla et al. 2000; Pinto et al.
2010; Tesfaigzi et al. 2006).
The gene encoding for MMP-9 is located in chromo-
some 20 q13.12. It is composed of approximately 7.6
kilobase pairs, arranged in 13 exons (Collier et al. 1991).
The first studies on the presumable role of MMP-9 poly-
morphisms were focused on SNPs located in the promoter
region of this gene (Zhang et al. 1999). Subsequent
research revealed at least four potential clinically relevant
SNPs in the promoter, and at least another five, which have
been found in the coding region (Grzela et al. 2011; Ye
2000, 2006). Nowadays, among over a dozen MMP-9
SNPs, the -1562 C/T SNP in the promoter sequence is the
most frequently studied and best recognized polymorphism
in the MMP-9 gene. Several reports suggested the impor-
tance of the common C/T substitution in the -1562
nucleotide of the MMP-9 promoter for gene transcription
rate and protein level (Medley et al. 2004; Sampsonas et al.
2007). Interestingly, although recognized as risk factor in
cancer metastasis, coronary artery disease, or aortic
aneurysm formation, in COPD and asthma the mentioned
SNP did not reveal any correlation with the prevalence and
severity of diseases in Caucasian (Holla et al. 2000) or
German populations (Ganter et al. 2005). However, two
other reports suggested an association of MMP-9 -1562 T
allele with higher susceptibility to COPD in non-Hispanic
whites (Tesfaigzi et al. 2006) and Korean patients (Lee
et al. 2010). None of the conducted studies have reported
any correlation between other recognized SNPs in the
promoter region, including -1831 T/A or -1702 T/A, and
the susceptibility to asthma (Ganter et al. 2005).
While polymorphisms of the promoter region may
influence the expression level of the target gene, the SNPs
located within the coding sequence are potent modifiers of
Arch. Immunol. Ther. Exp. (2016) 64:47–55 51
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the biological properties of the final protein product. The in
silico analysis of the putative impact of single amino acid
replacement on the 3D structure and biological properties
of the MMP-9 have suggested possible clinical relevance
of several known polymorphisms of this enzyme. One of
them concerns the 279th amino acid from the fibronectin-
like domain of MMP-9 molecule, where the non-charged
glutamine (Q) is replaced with a charged arginine (R).
Thus, it is labeled as MMP-9 279 Q/R SNP. This particular
SNP very likely affects the final structure of the enzyme
and may result in its increased affinity to the substrate. The
small study by Ganter et al. (2005) did not reveal any
association between 279 Q/R SNP and asthma. How-
ever, subsequent studies in a large group of over 4000
children with asthma (Pinto et al. 2010) and COPD and
suffering US veterans from New Mexico (Tesfaigzi et al.
2006) have shown a higher frequency of 279R allele in
individuals affected by the mentioned diseases.
Another potentially functional MMP-9 574 P/R poly-
morphism is located in the hemopexin domain of the
MMP-9 molecule. It was suggested that the substitution of
proline (P) with arginine (R) in this SNP may attenuate the
MMP-9 enzymatic activity. However, no relationship
between the mentioned polymorphism and COPD or
asthma and asthma-associated allergic rhinitis has been
reported so far (Inoue et al. 2012).
MMP-9 Modulators: the Future Perspectives?
The activity of MMPs is tightly controlled under physio-
logical conditions by a number of natural factors. Apart
from the specific TIMPs there are several other molecules,
displaying MMP-attenuating properties. They include a2-
macroglobulin, serpin E1/plasminogen-activator inhibitor-
1, reversion-inducing cysteine-rich protein with Kazal
motifs and tissue-factor-pathway-inhibitor 2 (Grzela et al.
2011; Litwiniuk et al. 2012). Moreover, several exogenous
MMP modulators have also been developed. It is note-
worthy that some of them are already used in clinical
practice; however, their primary indication was different
from the modulation of MMPs (Chakraborti et al. 2003;
Fanjul-Ferna´ndez et al. 2010).
The first pharmacological interventions, directed against
MMP-9 activity, have concerned synthetic proteinase
inhibitors (e.g., batimastat, marimastat and ilomastat),
originally aimed to prevent tumor metastases and tumor-
related angiogenesis (Shono et al. 1998). However, due to
numerous adverse events and relatively poor clinical
effectiveness, they were not introduced to routine clinical
use. Recently, natural MMP-9 antagonist, neovastat (AE-
941), was found to reveal some beneficial properties in
murine model of asthma (Lee et al. 2005).
Tetracyclines are natural antibiotics derived from
Streptomyces. Besides their antimicrobial effects, tetracy-
clines are also able to inhibit MMPs activity by directly
binding to their catalytic site. However, the studies on
putative anti-MMP effects of tetracyclines are not consis-
tent, and their inhibitory potential has not been fully
confirmed (Curci et al. 1998; Ding et al. 2005).
The inhibitors of hydroxymethylglutaryl-coenzyme A
reductase, widely known as statins, became recently a
golden standard in the treatment of hypercholesterolemia
and coronary artery disease. Besides their main hypoli-
pemic action, statins, especially simvastatin and
cerivastatin, reveal some poorly defined anti-inflammatory
properties, including suppression of MMP-9 production in
myocytes, neutrophils and macrophages (Nagashima et al.
2002).
The large group of potent MMP modulators was origi-
nally developed to regulate the function of the renin–
angiotensin system in the management of arterial hyper-
tension. However, the inhibitors of angiotensin-converting
enzyme (ACE) are also well-known suppressors of MMPs
activity, with a mechanism of action based on direct, dose-
dependent blockage of the catalytic domain (Grzela et al.
2011). Another group of renin–angiotensin modulators
comprises antagonists of angiotensin II receptor. They
were shown to decrease the MMP expression, possibly due
to suppression of the NF-jB pro-inflammatory pathways
(Fujiwara et al. 2008).
Although the inhibition of the renin–angiotensin system
may be considered as a novel therapeutic approach
(Shrikrishna et al. 2012), nevertheless, determination of its
clinical usefulness in COPD and asthma still requires fur-
ther studies. This is especially important in the context of
recent research concerning the insertion/deletion poly-
morphism of ACE (Ding et al. 2012), as well as the
discovery of ACE2, the homolog of ACE (Kaparianos and
Argyropoulou 2011). However, this issue is out of range of
this review.
The airway remodeling in COPD and asthma is associ-
ated with the abnormal response of epithelium and other
cellular components of the respiratory tract wall to noxious
agents. There is still an open question, whether the
remodeling results from inflammation or should rather be
considered as parallel or even a primary process, which may
precede clinical symptoms. Despite several differences,
COPD and asthma reveal some resemblance, especially in
their exacerbations and severe stages, where similar
mechanisms and similar factors may be involved. Among
various mediators involved in the progression of both the
diseases are pro-inflammatory cytokines/chemokines,
growth factors and proteases, including MMP-9. Moreover,
there is growing evidence supporting the role of genetic
predispositions in the development and progression of
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COPD and asthma. Therefore, better recognition of clinical
relevance of the mentioned data may provide new oppor-
tunities for earlier diagnosis and more effective treatment.
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